2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5874 Serum proteomic remodeling links TNFSF11, B-cell-associated proteins, and soluble PD1 to CD19 CAR T-cell efficacy in large B-cell lymphoma

Mohannad H Alkhatib, Luca Paruzzo, MD2, Federico Stella, MD3, Marijana Rucevic4, zahedeh bashardanesh5, Heng Quian6, Antonio Imparato, MD7, Priyamvada Das8, Vitor B. de Souza9, Zhixuan Zheng10, Elise A. Chong, MD11, Daniel Landsburg, MD12, Sunita Dwivedy Nasta, MD, MS13, Jordan S Carter, MD14, Colin J. Thomas, MD15, Rohith Raali16, Matthew Ho, MBChB17, Emeline R Chong, BA18, Alberto Carturan, MD19, Joseph Fraietta, PhD20, Patrizia Porazzi, PhD21, Stefan K Barta, MD22, Jakub Svoboda, MD23, Stephen J Schuster, MD24, Marco Ruella, MD25
1 Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 Olink proteomics, Thermo Fisher Scientific, Uppsala, Sweden
5 Olink proteomics, Thermo Fisher Scientific, Uppsala, Sweden
6 Olink proteomics, Thermo Fisher Scientific, Uppsala, Sweden
7 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, United States
11 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
12 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
13 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
14 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
15 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
16 Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, United States
17 Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, United States
18 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
19 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
20 Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, United States
21 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
22 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
23 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
24 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
25 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Background: Blood serum is a critical environment where immune cells, including chimeric antigen receptor T cells (CART), get activated, proliferate, and traffic through tissues. Blood serum composition and, in particular, its protein components are shaped not only by circulating blood cells but predominantly by the activity and condition of peripheral tissue. Blood serum proteomic analysis could capture a snapshot not only of the status of the immune system but also of peripheral organ function, inflammation, and the activity of the tumor. We hypothesized that longitudinal serum proteomic profiling could define treatment-induced local and systemic changes and identify soluble determinants of CART19 efficacy and failure.

Methods: To this goal, we used a high-throughput proteomics platform (Olink Explore HT) to evaluate 5,416 serum proteins from 97 LBCL patients at lymphodepletion (PRE-LD, n=52), CART19 infusion (day 0=91), and days + 7 (n=78), +14 (n=60), and +28 (n=60) following CART19. Proteins were quantified using Normalized Protein Expression unit (NPX). Differential protein expression, pathway enrichment, linear mixed-effects models, Kaplan-Meier analyses, and multivariable Cox regression were used.

Results: We profiled 97 LBCL patients treated with CART19 (03/2014-08/2024). Median age: 63 years; 63% were male. The median number of prior treatments was 3; 21% of the patients received second-line CART19. LDH was elevated in 32% of the cohort. Eighty percent of the patients received bendamustine LD and 20% cyclophosphamide-based (Cy-based) LD. Fifty-two percent of patients had a complete response (CR) as best response.

We first characterized treatment-induced serum proteomic changes. Overall, 462 (8.5%)  unique proteins changed significantly from PRE-LD through D28. Using PRE-LD as the reference, the greatest remodeling occurred at D0, reflecting lymphodepletion, and D7, coinciding with CART19 expansion. Compared with PRE-LD, 94 and 311 unique proteins were differentially expressed at D0 and D7. After D7, the serum proteome progressively returned to baseline. GO Biological process pathway analysis showed suppression of T-cell-and NK-cell-mediated immune pathways from PRE-LD to D0, with concurrent enrichment of cytokine and chemokine signaling. Consistently, GZMA, LCK, KLRD1, and KLRB1 decreased, whereas IL15, CXCL16, GDF15, and EDA2R increased. Cy-based LD induced larger proteomic changes than bendamustine LD, including significantly greater changes in IL15, CXCL16, KLRB1, and KLRD1. At D7, T-cell cytotoxicity and chemokine pathways were enriched, with increased GZMB, GZMA, GNLY, IL3, and IL10.

We next evaluated whether the serum proteome was associated with CART19 efficacy. At D0, TNFSF11 was significantly higher in CR patients than in PR/PD (log2FC=0.99; P<0.001). Using maximally selected rank statistics, we identified a D0 TNFSF11 cutoff of −1.07 NPX. Patients with high TNFSF11 had significantly longer median PFS than those with low TNFSF11 (16 vs 3 months; P<0.001). On multivariable analysis adjusting for age, CART product, number of prior therapies, and LDH, low TNFSF11 remained independently associated with inferior PFS (adjusted HR, 2.52; p=0.001). This association is biologically supported by prior preclinical evidence that TNFSF11 enhances antitumor immunity in checkpoint inhibitor models (Santamaria et al., 2024).

Finally, we investigated how longitudinal changes in the serum proteome were associated with clinical response. Patients achieving CR had consistently lower levels of B-cell-associated proteins. A composite B-cell score (CD20, CD22, and CD79b) declined over time in both groups but remained lower in CR than in PR/PD (p_group=0.007), suggesting the potential for an easily accessible measure of residual B-cell antigen burden. At D28, soluble PD-1 was increased in PR/PD patients (p=0.008), linking early T-cell dysfunction with CART19 failure.

Conclusions: Longitudinal serum proteomics revealed a coordinated trajectory of lymphodepletion-induced immune suppression, D7 immune activation, and D28 contraction after CART19. Elevated TNFSF11 was independently associated with longer PFS, whereas persistently higher B-cell-associated protein levels and increased soluble PD-1 characterized treatment failure. These findings support serum proteomics to monitor treatment biology, refine risk stratification, and track early CART19 failure, potentially informing earlier intervention and post-CART management.

 

Luca Paruzzo, MD: University of Pennsylvania - Patents & Royalties